Abstract:Background In this study, a combination of recombinant adenoviral p53 (rAd-p53) gene therapy and intra-arterial delivery of chemotherapeutic agents for treatment of oral squamous cell carcinoma was evaluated. Methods In total, 99 patients with stage III or IV oral carcinoma who had refused or were ineligible for surgery were enrolled in a randomized, placebo-controlled, double-blind, phase III clinical trial. They were randomly assigned to group I (n = 35; intra-arterial infusion of rAd-p53 plus chemotherapy), group II (n = 33; intra-arterial infusion of rAd-p53 plus placebo chemotherapy), or group III (n = 31; intra-arterial infusion of placebo rAd-p53 plus chemotherapy). Results The median length of follow-up was 36 months (range, 3 to 86 months). During follow-up, 16 patients in group I, 20 in group II, and 22 in group III died. Group I (48.5%) had a higher complete response rate than groups II (16.7%) and III (17.2%) ( P = 0.006). The rate of non-responders in group I was significantly lower than that in groups II and III ( P < 0.020). A log-rank test for survival rate indicated that group I had a significantly higher survival rate than group III ( P = 0.019). The survival rate of patients with stage III but not stage IV oral cancer was significantly higher in group I than in group III ( P = 0.015, P = 0.200, respectively). The survival rate of patients with stage IV did not differ significantly among the three groups. Or the 99 patients, 63 patients experienced adverse events of either transient flu-like symptoms or bone marrow suppression, while 13 patients had both these conditions together. No replication-deficient virus was detected in patient serum, urine, or sputum. rAd-p53 treatment increased Bax expression in the primary tumor of 80% of patients, as shown by immunohistochemical staining. Conclusions Intra-arterial infusion of combined rAd-p53 and chemotherapy significantly increased the survival rate of patients with stage III but not stage IV oral cancer, compared with intra-arterial chemotherapy. Intra-arterial infusion of combined rAd-p53 and chemotherapy may represent a promising alternative treatment for oral squamous cell carcinoma. Trial registration ChiCTR-TRC-09000392 (Date of registration: 2009-05-18).

Multicenter, Open-End, Randomized Controlled Study Using P53 Gene Recombinant Adenovirus Injection (Rad-P53) Combined with Chemotherapy for Orofacial Carcinoma (OFC): Phase IV Clinical Trial—progress Report and Conclusion.

Intra-Arterial Infusion Of Recombinant Adenoviral Human P53 Gene Combined Chemotherapy For Advanced Oral Cancer: A Phase Ii Double-Blind Randomized Clinical Trial.

726. Clinical Trial of Recombinant Adenovirus-p53 (Gendicine) Combined with Radiotherapy in Nasopharyngeal Carcinoma Patients

Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial

Preoperative Recombinant Adenoviral Human P53 Gene Combined with Intensity-Modulated Radiation Therapy in Treatment of Stage IV Papillary Thyroid Carcinoma: A Randomized Clinical Study.

[Recombinant Adenovirus-P53 Gene Therapy Combined with Radiotherapy for Head and Neck Squamous-Cell Carcinoma].

Therapy of Rad-P53 with Chemotherapy for Advanced Oral Carcinoma by Selective Intra-Arterial Infusion

Effect of Recombinant Adenovirus-P53 Combined with Radiotherapy on Long-Term Prognosis of Advanced Nasopharyngeal Carcinoma

47. A Combination Therapy of Selective Intraarterial Gendicine Infusion with Chemotherapy for Locally Advanced Head and Neck Carcinoma

Clinical Effect of Recombinant Adenovirus-p53 Combined with Hyperthermia for Advanced Soft Tissue Sarcoma

Clinical Effectiveness of Recombinant Adenovirus-P53 Combined with Radiotherapy in Advanced Soft Tissue Sarcoma: A Report of 37 Cases

Safety and Primary Efficacy of Recombinant Human Adenovirus-P53 Injection on Advanced Solid Tumor

Clinical Observation of the Effect of Recombinant Adenovirus-p53 plus Radio-thermotherapy on Soft Tissue Sarcoma

Effect and Safety of Recombinant Adenovirus-p53 Transfer Combined with Radiotherapy on Long-Term Survival of Locally Advanced Cervical Cancer.

Clinical Effect of Rad-P53 Combined with Radiotherapy and Chemotherapy on Treatment of Advanced Nasopharyngeal Carcinoma

[Recombinant Adenovirus P53 Agent Injection Combined with Radiotherapy in Treatment of Nasopharyngeal Carcinoma: a Phase II Clinical Trial].

Combination of Recombinant Adenovirus-P53 with Radiochemotherapy in Unresectable Pancreatic Carcinoma

Clinical Results of Recombinant Adenoviral Human P53 Gene in Treatment of Malignant Pleural Effusions Caused by Advanced Lung Cancers.

Recombinant adenovirus-p53 enhances the therapeutic effect of surgery and chemoradiotherapy combination in hypopharyngeal squamous cell carcinomas patients.

Effects of Recombinant Adenovirus-p53 Combined with Oxaliplatin on Growth Inhibition of Human Gastric Cancer Cell Line SGC-7901

Clinical efficacy and safety of recombinant adenovirus-p53 combined with concurrent radiotherapy and hyperthermia in treatment of advanced soft tissue sarcoma:a study of 76 patients